| Literature DB >> 28363498 |
Jacob Amersfoort1, Johan Kuiper2.
Abstract
This review discusses the relevant metabolic pathways and their regulators which show potential for T cell metabolism-based immunotherapy in diseases hallmarked by both metabolic disease and autoimmunity. Multiple therapeutic approaches using existing pharmaceuticals are possible from a rationale in which T cell metabolism forms the hub in dampening the T cell component of autoimmunity in metabolic diseases. Future research into the effects of a metabolically aberrant micro-environment on T cell metabolism and its potential as a therapeutic target for immunomodulation could lead to novel treatment strategies for metabolic disease-associated autoimmunity.Entities:
Keywords: Autophagy; Cellular metabolism; Diabetes; Dyslipidemia; T cells; Therapeutics
Mesh:
Year: 2017 PMID: 28363498 DOI: 10.1016/j.imbio.2017.03.001
Source DB: PubMed Journal: Immunobiology ISSN: 0171-2985 Impact factor: 3.144